Top

Published in:

Open Access 03-07-2023 | Heparin | Original Article

Anti-Xa level monitoring of low-molecular-weight heparin during intermittent venovenous hemofiltration

Authors: Lengnan Xu, Ying Sun, Songlan Wang, Chuanbao Li, Yonghui Mao

Published in: Annals of Hematology | Issue 8/2023

Abstract

Low-molecular-weight heparin (LMWH) is an anticoagulant used to prevent clotting during blood purification treatments. This study aimed to evaluate the clinical use of the anti-factor Xa level (anti-Xa) for monitoring LMWH anticoagulant levels during intermittent venovenous hemofiltration (IVVHF). This prospective observational study enrolled patients who required IVVHF for renal failure in Beijing Hospital between May 2019 and February 2021. The LMWH anticoagulation was assessed by the coagulation grade of the filter and line. One hundred and ten participants were included. There were 90 patients with a filter and line coagulation grade of ≤ 1 and 20 patients with grade > 1. The anti-Xa level of 0.2 IU/mL was a critical value. The multivariable logistic regression analysis showed that anti-Xa level > 0.2 IU/mL (odd ratio [OR] = 2.263; 95% CI: 1.290–4.871, P = 0.034) and cardiovascular disease (OR = 10.028; 95% CI: 1.204–83.488; P = 0.033) were independently associated with the coagulation grade of the filter and line. Anti-Xa level could monitor LMWH anticoagulation during IVVHF.

Tolwani A (2012) Continuous renal-replacement therapy for acute kidney injury. N Engl J Med 367:2505–2514. https://doi.org/10.1056/NEJMct1206045CrossRefPubMed

Chacko J (2008) Renal replacement therapy in the intensive care unit. Indian J Crit Care Med 12:174–180. https://doi.org/10.4103/0972-5229.45078CrossRefPubMedPubMedCentral

Pannu N, Klarenbach S, Wiebe N, Manns B, Tonelli M, Alberta Kidney Disease N (2008) Renal replacement therapy in patients with acute renal failure: a systematic review. JAMA 299:793–805. https://doi.org/10.1001/jama.299.7.793CrossRefPubMed

Zhang W, Bai M, Yu Y, Chen X, Zhao L, Chen X (2021) Continuous renal replacement therapy without anticoagulation in critically ill patients at high risk of bleeding: A systematic review and meta-analysis. Semin Dial 34:196–208. https://doi.org/10.1111/sdi.12946CrossRefPubMed

Singh S (2020) Anticoagulation during Renal Replacement Therapy. Indian J Crit Care Med 24:S112–S116. https://doi.org/10.5005/jp-journals-10071-23412CrossRefPubMedPubMedCentral

KDIGO Group (2012) KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl 2:1–138

Kellum JA, Lameire N (2018) The definition of acute kidney injury. Lancet 391:202–203. https://doi.org/10.1016/S0140-6736(17)31630-6CrossRefPubMed

Lazrak HH, René É, Elftouh N, Leblanc M, Lafrance JP (2017) Safety of low-molecular-weight heparin compared to unfractionated heparin in hemodialysis: a systematic review and meta-analysis. BMC Nephrol 18:187. https://doi.org/10.1186/s12882-017-0596-4CrossRefPubMedPubMedCentral

Lim W, Cook DJ, Crowther MA (2004) Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: a meta-analysis of randomized trials. J Am Soc Nephrol 15:3192–3206. https://doi.org/10.1097/01.Asn.0000145014.80714.35CrossRefPubMed

10.

Al-Saran KA, Sabry A, Taha M, Ghafour MA, Al Fawzan F (2010) Profile of low molecular weight tinzaparin sodium for anticoagulation during hemodialysis. Saudi J Kidney Dis Transpl 21:43–49PubMed

11.

Hao C, Sun M, Wang H, Zhang L, Wang W (2019) Low molecular weight heparins and their clinical applications. Prog Mol Biol Transl Sci 163:21–39. https://doi.org/10.1016/bs.pmbts.2019.02.003CrossRefPubMed

12.

Ashby D, Borman N, Burton J, Corbett R, Davenport A, Farrington K, Flowers K, Fotheringham J, Andrea Fox RN, Franklin G, Gardiner C, Martin Gerrish RN, Greenwood S, Hothi D, Khares A, Koufaki P, Levy J, Lindley E, Macdonald J et al (2019) Renal Association Clinical Practice Guideline on Haemodialysis. BMC Nephrol 20:379. https://doi.org/10.1186/s12882-019-1527-3CrossRefPubMedPubMedCentral

13.

Golper TA, Fissell R, Fissell WH, Hartle PM, Sanders ML, Schulman G (2014) Hemodialysis: core curriculum 2014. Am J Kidney Dis 63:153–163. https://doi.org/10.1053/j.ajkd.2013.07.028CrossRefPubMed

14.

EBPGE Group (2002) Section V. Chronic intermittent haemodialysis and prevention of clotting in the extracorporal system. Nephrol Dial Transplant 17 Suppl 7:63-71. https://doi.org/10.1093/ndt/17.suppl_7.63

15.

Hirsh J, Raschke R (2004) Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:188s–203s. https://doi.org/10.1378/chest.126.3_suppl.188SCrossRefPubMed

16.

Wu T, Xia X, Chen W, Fu J, Zhang J (2020) The effect of anti-Xa monitoring on the safety and efficacy of low-molecular-weight heparin anticoagulation therapy: A systematic review and meta-analysis. J Clin Pharm Ther 45:602–608. https://doi.org/10.1111/jcpt.13169CrossRefPubMed

17.

Babin JL, Traylor KL, Witt DM (2017) Laboratory Monitoring of Low-Molecular-Weight Heparin and Fondaparinux. Semin Thromb Hemost 43:261–269. https://doi.org/10.1055/s-0036-1581129CrossRefPubMed

18.

Tao M, Zheng D, Liang X, Ye M, Liu Y, Li Y, Shen H, He Q (2020) Evaluation of the anticoagulant effect of low-molecular-weight heparins based on the anti-Xa level during haemodialysis. Nephrology (Carlton) 25:723–729. https://doi.org/10.1111/nep.13697CrossRefPubMed

19.

Chen X (2021) Blood Purification Standard Operating Procedure (SOP) 2021 edn. People’s Medical Publishing House

20.

Mei C, Ye C, Rong S (2009) Practical Dialysis Handbook, 2nd edn. People’s Health Publishing House, Beijing

21.

Chen X (2010) Standard operating procedures for blood purification. People’s Military Medical Press, Beijing

22.

He C, Zhang X (1999) Renal Replacement Therapy. Shanghai Science and Technology Literature Publishing House, Shanghai

23.

Guillet B, Simon N, Sampol JJ, Lorec-Penet AM, Portugal H, Berland Y, Dussol B, Brunet P (2003) Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis. Nephrol Dial Transplant 18:2348–2353. https://doi.org/10.1093/ndt/gfg396CrossRefPubMed

24.

Aursulesei V, Costache II (2019) Anticoagulation in chronic kidney disease: from guidelines to clinical practice. Clin Cardiol 42:774–782. https://doi.org/10.1002/clc.23196CrossRefPubMedPubMedCentral

25.

Isla A, Gascón AR, Maynar J, Arzuaga A, Corral E, Martín A, Solinís MA, Muñoz JL (2005) In vitro and in vivo evaluation of enoxaparin removal by continuous renal replacement therapies with acrylonitrile and polysulfone membranes. Clin Ther 27:1444–1451. https://doi.org/10.1016/j.clinthera.2005.09.008CrossRefPubMed

26.

Garcia DA, Baglin TP, Weitz JI, Samama MM (2012) Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e24S–e43S. https://doi.org/10.1378/chest.11-2291CrossRefPubMedPubMedCentral

27.

Tsang DJ, Tuckfield A, Macisaac CM (2011) Audit of safety and quality of the use of enoxaparin for anticoagulation in continuous renal replacement therapy. Crit Care Resusc 13:24–27PubMed

28.

Bembea MM, Annich G, Rycus P, Oldenburg G, Berkowitz I, Pronovost P (2013) Variability in anticoagulation management of patients on extracorporeal membrane oxygenation: an international survey. Pediatr Crit Care Med 14:e77–e84. https://doi.org/10.1097/PCC.0b013e31827127e4CrossRefPubMedPubMedCentral

29.

Montalescot G, Collet JP, Tanguy ML, Ankri A, Payot L, Dumaine R, Choussat R, Beygui F, Gallois V, Thomas D (2004) Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation 110:392–398. https://doi.org/10.1161/01.Cir.0000136830.65073.C7CrossRefPubMed

30.

Becker RC, Spencer FA, Gibson M, Rush JE, Sanderink G, Murphy SA, Ball SP, Antman EM (2002) Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J 143:753–759. https://doi.org/10.1067/mhj.2002.120774CrossRefPubMed

31.

Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ (2012) Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:7s–47s. https://doi.org/10.1378/chest.1412S3CrossRefPubMedPubMedCentral

32.

Laposata M, Green D, Van Cott EM, Barrowcliffe TW, Goodnight SH, Sosolik RC (1998) College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med 122:799–807PubMed

33.

Brophy DF, Martin EJ, Gehr TW, Best AM, Paul K, Carr ME Jr (2006) Thrombin generation time is a novel parameter for monitoring enoxaparin therapy in patients with end-stage renal disease. J Thromb Haemost 4:372–376. https://doi.org/10.1111/j.1538-7836.2006.01731.xCrossRefPubMed

Title: Anti-Xa level monitoring of low-molecular-weight heparin during intermittent venovenous hemofiltration
Authors: Lengnan Xu
Ying Sun
Songlan Wang
Chuanbao Li
Yonghui Mao
Publication date: 03-07-2023
Publisher: Springer Berlin Heidelberg
Keywords: Heparin
Hemofiltration
Anticoagulant
Renal Replacement Procedures
Published in: Annals of Hematology / Issue 8/2023
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-023-05290-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2023

Patient preference for deferasirox film-coated versus dispersible tablet formulation: a sequential-design phase 2 study in patients with thalassemia

Real-life use of mTOR inhibitor-based therapy in adults with autoimmune cytopenia highlights strong efficacy in relapsing/refractory multi-lineage autoimmune cytopenia

Comparison of outcomes for patients with acute myeloid leukemia undergoing haploidentical stem cell transplantation in first and second complete remission

Toxicity Profile According to Etoposide and Cytarabine Dosing in Patients with Lymphoma Receiving Autologous Stem Cell Transplantation Following BEAM Conditioning

An adult case of systemic lupus erythematosus and cerebral vasculitis after umbilical cord blood transplantation for acute myeloid leukemia

Clinicopathological analysis and specific discriminating markers of interleukin detection in cerebrospinal fluid with primary central nervous system lymphoma: results from a retrospective study

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials